poisar

Stocks · News reference

Entrada Therapeutics Reports Third Quarter 2026 Financial Results

Entrada Therapeutics announced its financial results for the third quarter ended September 30, 2026, reporting a net loss of $39.7 million and providing updates on its clinical programs.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TRDA
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  4. Entrada Therapeutics, Inc.

    Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

    Entrada Therapeutics announced positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 for DMD patients amenable to exon 45 skipping. The trial met primary safety and tolerability objectives at the 5 mg/kg dose with favorable safety profile and demonstrated a 0.10% mean increase in dystrophin production. The company expects significant increases in dystrophin production at higher doses in future cohorts and plans to report Cohort 2 data (10 mg/kg) in the first half of 2027.

    TRDA
  5. Na

    Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

    Entrada Therapeutics announced that an independent Data Monitoring Committee has recommended advancing to Cohort 3 at the top dose of 18 mg/kg in the ELEVATE-44-201 Phase 1/2 clinical study of ENTR-601-44 for Duchenne muscular dystrophy. The dose escalation marks progress in understanding the drug's safety and efficacy profile. Cohort 1 data is expected by year-end 2026, with Cohort 2 data anticipated in Q1 2027.

    TRDA